Needham Rates Biogen (BIIB) buy, $256 Price Target

Analyst Ami Fadia keeps a Buy rating on the biotech giant, aligning with a broad group of optimistic analysts following the stock, a 18.17% upside from the current price.

By EarningsIQ Research Desk · Published Jun 29, 2026, 7:01 AM EDT · Updated Jul 1, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Needham rated Biogen Inc. ($BIIB) "buy" with a $256 price target on June 29, 2026.

Since the rating, $BIIB is down 3.8% after 1 week, down 3.4% after 1 month and up 7.4% to date (from the $216.63 close on Jun 29, 2026).

BIIB Biogen Inc.

$232.65 +30.83% year to date

Daily close · Oct 16, 2026

Key Points

Needham analyst Ami Fadia reiterated a Buy rating and a $256.00 price target for Biogen Inc. on June 29, 2026.
Needham's $256 price target implies 18.17% upside from Biogen Inc.'s ($BIIB) current $216.63 share price.
The stock is currently trading around $216.63, which sits between its 52-week low of $135.39 and its yearly high of $225.80.
Wall Street remains largely positive on the company, with 31 analysts providing a consensus Buy recommendation and an average price target of $238.18.

Get $BIIB trade alerts by text

We text you when insiders, Congress or big funds trade $BIIB. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Biogen Inc. alert may contain errors. Disclosures

On June 29, 2026, Needham analyst Ami Fadia reaffirmed a Buy rating on Biogen Inc. (BIIB) and set a price target of $256.00. This call follows a series of recent updates from other major firms that suggest a generally optimistic outlook for the Cambridge-based biotechnology leader. Fadia's target implies that the stock has significant room to run from its current levels on the Nasdaq.

Analyst rating track record

Needham vs. the S&P 500

YTD return +14.94% hypothetical

All-time return +83.15% S&P 500 +25.59%

vs. S&P 500 +57.56% ahead of the index

Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

Needham’s stance is part of a wider trend of positive sentiment on Wall Street. On October 12, 2026, JP Morgan upgraded Biogen to an Overweight rating and set a high-water mark price target of $300.00. Shortly before that, on October 9, 2026, UBS maintained its own Buy rating while raising its price target to $270.00. RBC Capital also weighed in on October 8, 2026, keeping an Outperform rating with a $256.00 target, a slight adjustment from their previous $260.00 mark.

Not every firm is as bullish, however. HSBC maintained a Reduce rating on September 10, 2026, with a much lower price target of $175.00. Despite that outlier, the broader consensus from 31 different analysts remains a Buy, with an average price target of $238.18. Other notable ratings include an Outperform from Wolfe Research with a $300.00 target and an Overweight from Piper Sandler at $245.00.

Biogen Stock Performance

On Monday, Biogen shares were priced at $216.63. The stock has shown resilience lately, staying well above its 52-week low of $135.39. It is currently trading near its 200-day moving average of $193.04 and its 50-day moving average of $210.96. With a market capitalization of about $32.37 billion, the company carries a price-to-earnings (P/E) ratio of 38.98, though its forward P/E is considerably lower at 13.25, suggesting better earnings potential in the year ahead.

12-month forecast

$BIIB price target

Biogen Inc. daily closes and this analyst's $256 target. Not advice.

Recent Earnings and Financial Health

Biogen reported revenue of $10.03 billion in its latest financial reporting period, representing a modest growth of 3.4%. These figures reflect the company's ability to remain profitable while investing in new drug pipelines, maintaining a net margin of 8.32% and a return on equity of 4.58%. The company’s balance sheet appears stable with a current ratio of 1.87, which measures its ability to cover short-term obligations. Investors are looking ahead to the October 28, 2026, earnings call to see if the company can maintain its revenue momentum.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

B- 71/100

Reported Apr 29, 2026

Forward outlook
5 target raises vs 1 cuts.
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
Pre-earnings setup
Expectations were about average.
Analyst signal
5 target raises, 1 target cut.
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.

Earnings Call Summary

Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.

Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.

Slightly positive report. The quarter was acceptable, but the forward setup is not strong.

Therapy Development and Market Focus

Biogen is a pioneer in neuroscience, focusing on some of the most difficult-to-treat conditions like Alzheimer’s disease, multiple sclerosis (MS), and spinal muscular atrophy. The company is perhaps best known for its MS portfolio, including drugs like Tecfidera and Tysabri, but it has recently expanded into new areas with Leqembi for Alzheimer’s and Zurzuvae for postpartum depression. Its success often hinges on high-stakes clinical trials and the ability to navigate complex regulatory approvals for these specialized therapies.

What to Watch at Biogen Inc.

Investors should keep an eye on the upcoming October 28 earnings report for updates on the rollout of newer products like Skyclarys and Leqembi. While analyst ratings provide a glimpse into professional expectations, they are opinions based on current data and can change as new clinical results or financial reports emerge. Further filings from institutional investors and insiders in the coming months will offer more clarity on how the market is positioning itself for Biogen's next phase of growth.